Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Allogene reports Q2 2026 results, cites ALPHA3 futility data and FDA designations for cema-celAug 12Quarterly updateAllogene Therapeutics